Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGeneDx Holdings Corp.

GeneDx Holdings Corp.

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
55.3 USD 0.47 ( 0.86%)
Last update at 2026-11-11T20:57:00Z
VOLUME
745330
Market Cap
2822.41M

Momentum Score

…

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
54.73
Low
59.72
High
52 Week Price Range
32.21
Low
170.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

GeneDx Holdings Corp. operates clinical genomic testing laboratories that provide next-generation sequencing-based diagnostic services, specializing in rare disease, pediatric and hereditary testing. Growth may be supported by wider adoption of genomic medicine, expanding indications and improving payer coverage; investors may find the company attractive for its sequencing expertise and variant interpretation database.
Principal risks are reimbursement and regulatory uncertainty, strong competition from larger diagnostics firms and new entrants, operational scale-up challenges and reliance on maintaining accurate variant interpretation and turnaround times.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
54.83
Dividend Yield
-
Revenue TTM
454.43M
Revenue Per Share
15.55
Gross Profit TTM
315.30M
Debt / Equity
0.49
ROE
-40.80%
Net Debt
46.95M
ROCE
-4.03%
Diluted EPS TTM
-3.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.14M -52.63M -176.69M -598.03M -245.39M
Net income -21.02M -52.29M -175.77M -548.98M -245.39M
Selling general administrative 150.82M 101.11M 133.75M 203.33M 205.99M
Selling and marketing expenses 88.41M 67.37M 60.96M 134.91M 112.74M
Gross profit 298.17M 194.40M 90.01M -26.75M -16.60M
Reconciled depreciation 25.22M 21.95M 33.73M 59.31M 21.81M
Ebit -18.60M -49.60M -170.19M -667.65M -446.15M
Ebitda 6.63M -27.64M -136.46M -395.60M -424.34M
Depreciation and amortization 25.22M 21.95M 33.73M 272.05M 21.81M
Non operating income net other - - - 72.83M -
Operating income -11.80M -23.21M -180.60M -667.65M -446.15M
Other operating expenses 439.34M 328.66M 383.16M 692.20M 658.34M
Interest expense 2.54M 3.03M - 3.21M 2.83M
Tax provision -0.12M -0.34M -0.93M -49.05M 0.00M
Interest income - - - 2.54M 0.08M
Net interest income -2.54M -3.03M 1.11M -0.67M -2.76M
Non recurring - - - 210.15M -
Income tax expense -0.12M -0.34M -0.93M -49.05M -203.59M
Total revenue 427.54M 305.45M 202.57M 234.69M 212.19M
Total operating expenses 311.25M 217.61M 270.60M 430.76M 429.55M
Cost of revenue 129.37M 111.05M 112.56M 261.44M 228.80M
Total other income expense net -9.34M -29.42M 3.90M 69.62M 200.76M
Net income from continuing ops -21.02M -52.29M -175.77M -548.98M -245.39M
Net income applicable to common shares - - - -548.98M -245.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 570.19M 419.38M 473.67M 490.94M 554.09M
Intangible assets 168.48M 158.60M 172.62M 186.65M -
Other current assets 8.69M 8.50M 10.60M 6.39M 3.80M
Total liab 262.01M 174.13M 245.66M 237.24M 165.99M
Total stockholder equity 308.18M 245.25M 228.02M 253.71M 388.10M
Deferred long term liab - - - 2.66M -
Other current liab 97.50M 43.53M 44.44M 92.12M 52.70M
Common stock 0.00M 0.00M 0.00M 0.04M 0.02M
Capital stock 0.00M 0.00M 0.00M 0.04M 0.02M
Retained earnings -1373.49M -1352.47M -1300.19M -1124.42M -575.44M
Other liab - - - 26.68M 53.71M
Good will 13.52M 0.00M - - -
Other assets - - 0.00M 7.38M 7.83M
Cash 105.00M 85.21M 99.68M 123.93M 400.57M
Total current liabilities 108.91M 54.82M 58.82M 144.30M 101.28M
Current deferred revenue - - - 0.04M 0.47M
Net debt 46.95M 30.96M 20.09M -51.55M -367.72M
Short term debt 8.95M 3.34M 4.14M 6.12M 3.42M
Short long term debt 4.54M 1.21M 0.50M 4.75M -
Short long term debt total 151.95M 116.17M 119.77M 72.38M 32.85M
Other stockholder equity 1680.74M 1596.89M 1527.78M 1378.09M 963.52M
Property plant equipment - - - 84.28M 62.72M
Total current assets 268.29M 197.97M 182.34M 212.62M 483.54M
Net tangible assets - - - 253.71M 388.10M
Short term investments 66.28M 55.97M 30.47M - -
Net receivables 74.37M 37.63M 32.82M 43.34M 26.56M
Long term debt 48.18M 51.91M 52.69M 6.25M 11.00M
Inventory 13.95M 10.65M 8.78M 13.66M 33.46M
Accounts payable 2.46M 7.95M 10.24M 46.02M 44.69M
Accumulated other comprehensive income 0.94M 0.83M 0.42M - -
Common stock total equity - - - 0.04M -
Retained earnings total equity - - - -1124.42M -
Non currrent assets other 3.32M 4.31M 3.43M 7.38M 7.83M
Non current assets total 301.90M 221.41M 291.33M 278.32M 70.55M
Capital lease obligations 60.45M 64.25M 66.58M 66.13M 21.85M
Long term debt total - - - 6.25M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -9.64M -30.13M -41.70M -141.33M -20.79M
Change to liabilities - - - 14.99M 24.61M
Total cashflows from investing activities -61.52M -30.13M -43.73M -141.33M -20.79M
Net borrowings -3.66M -3.23M 42.95M -3.29M -13.47M
Total cash from financing activities 48.02M 44.16M 186.24M 197.31M 493.73M
Change to operating activities - - - -8.02M -11.44M
Net income -21.02M -52.29M -175.77M -548.98M -245.39M
Change in cash 19.79M -14.47M -37.72M -263.17M 282.51M
Begin period cash flow 86.20M 100.67M 137.40M 401.47M 118.96M
End period cash flow 105.99M 86.20M 99.68M 138.30M 401.47M
Total cash from operating activities 33.28M -28.50M -180.15M -319.15M -190.43M
Issuance of capital stock 46.70M 46.50M -54.66M 0.00M 442.68M
Depreciation 25.22M 21.95M 35.83M 59.31M 21.81M
Other cashflows from investing activities - - -0.00M -134.17M -
Change to inventory -3.44M -2.58M 0.97M 4.60M -10.62M
Change to account receivables -36.23M -5.42M 10.26M 5.53M 5.54M
Sale purchase of stock - - - 200.61M -
Other cashflows from financing activities 48.02M 0.89M 0.28M 200.61M 64.51M
Change to netincome - - - 133.89M 25.00M
Capital expenditures 19.02M 5.49M 5.71M 14.32M 20.79M
Change receivables - - - 5.53M -
Cash flows other operating - - - 13.24M -
Cash and cash equivalents changes - - - -263.17M -
Change in working capital -15.60M -24.75M -38.24M 36.13M 8.08M
Stock based compensation 32.16M 9.14M -0.33M 41.98M 219.42M
Other non cash items 12.51M 17.79M -0.72M 141.53M 1.62M
Free cash flow 14.26M -33.99M -185.86M -333.48M -211.22M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WGS
GeneDx Holdings Corp.		 0.47
0.86%		 55.30 - 66.67 6.21 10.96 5.97 161.17
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

GeneDx Holdings Corp.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

North Tower, Stamford, CT, United States, 06902

888 729 1206

https://www.genedx.com

1300

Name Title Year Born
Ms. Katherine A. Stueland President, CEO & Director 1976
Mr. Kevin Feeley Chief Financial Officer NA
Ms. Karen Ponchner Senior VP & Head of Operations NA
Mr. Eric Olivares Ph.D. Chief Product & Technology Officer NA
Mr. Devin K. Schaffer J.D., M.B.A. General Counsel NA
Mr. Paul Kruszka M.D. Chief Medical Officer NA
Ms. Melanie Duquette Chief Growth Officer NA
Sabrina Dunbar Chief of Staff NA
Ms. Katherine A. Stueland CEO & Director 1976
Mr. Kevin Feeley CPA Chief Financial Officer 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…